Denali Therapeutics Inc (DNLI)

$26.48 +0.80 (3.12%)
Market Cap 4.08B
Revenue (ttm) 0.00
Net Income (ttm) -512.54M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,894,500
Avg Vol 1,922,318
Day's Range N/A - N/A
Shares Out 158.71M
Stochastic %K 68%
Beta 0.96
Analysts Strong Sell
Price Target $33.87

Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement thera...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 866 8547
Address:
161 Oyster Point Boulevard, South San Francisco, United States
Latest News on DNLI
Denali Therapeutics price target raised to $26 from $20 at Wedbush

2026-07-13T12:05:08.000Z - 14 hours ago

Denali Therapeutics price target raised to $26 from $20 at Wedbush

Denali Therapeutics resumed with an Overweight at JPMorgan

2026-07-13T09:50:38.000Z - 16 hours ago

Denali Therapeutics resumed with an Overweight at JPMorgan

Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Jul 9, 2026, 4:01 PM EDT - 4 days ago

Denali Therapeutics to Give Opening Plenary Address at Alzheimer's Association International Conference (AAIC) 2026 and Highlight Breakthroughs in Delivering Biologic Therapies Across Blood-Brain Barrier

Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV

2026-06-18T12:14:55.000Z - 25 days ago

Denali Therapeutics enters agreement to sell Rare Pediatric Disease PRV

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Jun 18, 2026, 8:00 AM EDT - 25 days ago

Denali Therapeutics Enters Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $195 Million

Denali Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 1:00 PM EDT - 4 weeks ago

Denali Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Denali Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 4, 2026, 8:45 AM EDT - 5 weeks ago

Denali Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Denali Therapeutics Transcript: AGM 2026

Jun 3, 2026, 1:00 PM EDT - 5 weeks ago

Denali Therapeutics Transcript: AGM 2026

Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley

2026-05-22T18:35:52.000Z - 7 weeks ago

Denali Therapeutics price target lowered to $35 from $40 at Morgan Stanley

Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank

2026-05-22T13:31:04.000Z - 7 weeks ago

Denali Therapeutics price target lowered to $31 from $35 at Deutsche Bank

Denali Therapeutics trading resumes

2026-05-21T22:35:11.000Z - 7 weeks ago

Denali Therapeutics trading resumes

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

2026-05-21T22:05:12.000Z - 7 weeks ago

Biogen and Denali’s Parkinson’s candidate did not meet Phase 2b endpoints

BIIB

Denali Therapeutics trading halted, news pending

2026-05-21T21:55:12.000Z - 7 weeks ago

Denali Therapeutics trading halted, news pending

Denali Therapeutics price target lowered to $40 from $42 at Morgan Stanley

2026-05-14T16:46:35.000Z - 2 months ago

Denali Therapeutics price target lowered to $40 from $42 at Morgan Stanley

Denali Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

May 12, 2026, 6:00 PM EDT - 2 months ago

Denali Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

Denali Therapeutics Slides: Corporate presentation

May 12, 2026, 4:00 PM EDT - 2 months ago

Denali Therapeutics Slides: Corporate presentation

Denali Therapeutics price target lowered to $23 from $25 at Wedbush

2026-05-08T13:55:36.000Z - 2 months ago

Denali Therapeutics price target lowered to $23 from $25 at Wedbush

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

May 7, 2026, 4:01 PM EDT - 2 months ago

Denali Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

Denali Therapeutics Quarterly report: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Denali Therapeutics Quarterly report: Q1 2026

Denali Therapeutics Earnings release: Q1 2026

May 7, 2026, 7:00 AM EDT - 2 months ago

Denali Therapeutics Earnings release: Q1 2026

Denali Therapeutics Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Denali Therapeutics Proxy statement: Proxy filing

Denali Therapeutics Proxy statement: Proxy filing

Apr 21, 2026, 8:00 AM EDT - 2 months ago

Denali Therapeutics Proxy statement: Proxy filing

Denali Therapeutics price target raised to $34 from $32 at Baird

2026-04-07T10:20:12.000Z - 3 months ago

Denali Therapeutics price target raised to $34 from $32 at Baird

Denali Therapeutics price target raised to $39 from $38 at BTIG

2026-04-06T17:15:09.000Z - 3 months ago

Denali Therapeutics price target raised to $39 from $38 at BTIG

Denali Therapeutics regains full rights to DNL593

2026-04-06T01:15:08.000Z - 3 months ago

Denali Therapeutics regains full rights to DNL593

TAK

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Apr 3, 2026, 1:30 PM EDT - 3 months ago

Denali Therapeutics Regains Full Rights to Investigational Therapy DNL593 (PTV:PGRN) for GRN-related Frontotemporal Dementia (FTD-GRN)

Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank

2026-03-26T12:42:31.000Z - 3 months ago

Denali Therapeutics price target raised to $35 from $26 at Deutsche Bank

Denali Therapeutics price target raised to $42 from $32 at H.C. Wainwright

2026-03-26T11:25:52.000Z - 3 months ago

Denali Therapeutics price target raised to $42 from $32 at H.C. Wainwright

Denali Therapeutics price target raised to $42 from $40 at Morgan Stanley

2026-03-26T10:50:10.000Z - 3 months ago

Denali Therapeutics price target raised to $42 from $40 at Morgan Stanley

Denali Therapeutics price target raised to $31 from $29 at BofA

2026-03-26T10:45:25.000Z - 3 months ago

Denali Therapeutics price target raised to $31 from $29 at BofA

Denali Therapeutics price target raised to $41 from $34 at Stifel

2026-03-26T10:35:47.000Z - 3 months ago

Denali Therapeutics price target raised to $41 from $34 at Stifel

Denali Therapeutics Transcript: Study update

Mar 25, 2026, 12:30 PM EDT - 3 months ago

Denali Therapeutics Transcript: Study update

Denali Therapeutics Press release: Study update

Mar 25, 2026, 12:30 PM EDT - 3 months ago

Denali Therapeutics Press release: Study update

Denali Therapeutics Slides: Study update

Mar 25, 2026, 12:30 PM EDT - 3 months ago

Denali Therapeutics Slides: Study update

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

Mar 25, 2026, 11:50 AM EDT - 3 months ago

Denali Therapeutics Announces U.S. FDA Approval of AVLAYAH™ (tividenofusp alfa-eknm) for Treatment of Hunter Syndrome (MPS II)

Denali Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 17, 2026, 2:00 PM EDT - 4 months ago

Denali Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Denali Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 9, 2026, 3:40 PM EDT - 4 months ago

Denali Therapeutics Transcript: Leerink Global Healthcare Conference 2026

FDA reversals leave investors worrying about the fates of other experimental drugs

Mar 6, 2026, 11:33 AM EST - 4 months ago

FDA reversals leave investors worrying about the fates of other experimental drugs

MRNA RGNX WVE

Denali Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 9:50 AM EST - 4 months ago

Denali Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Feb 26, 2026, 4:01 PM EST - 4 months ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

Denali Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 4 months ago

Denali Therapeutics Earnings release: Q4 2025

Denali Therapeutics Annual report: Q4 2025

Feb 26, 2026, 7:00 AM EST - 4 months ago

Denali Therapeutics Annual report: Q4 2025

Denali Therapeutics Transcript: Study update

Feb 5, 2026, 3:30 PM EST - 5 months ago

Denali Therapeutics Transcript: Study update

Denali Therapeutics Press release: Study update

Feb 5, 2026, 3:30 PM EST - 5 months ago

Denali Therapeutics Press release: Study update

Denali Therapeutics Slides: Study update

Feb 5, 2026, 3:30 PM EST - 5 months ago

Denali Therapeutics Slides: Study update

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Feb 5, 2026, 2:00 PM EST - 5 months ago

Denali Therapeutics Presents Enzyme TransportVehicle™ Progress Across Three Clinical Programs for Treatment of Lysosomal Storage Disorders at 2026 WORLDSymposium™

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Feb 2, 2026, 8:00 AM EST - 5 months ago

Denali Therapeutics To Host Webcast Highlighting Presentations on Enzyme TransportVehicle™ Programs at the 2026 WORLDSymposium™

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Jan 29, 2026, 4:00 PM EST - 5 months ago

Denali Therapeutics Announces Data Presentations on Enzyme TransportVehicle™ Programs for Hunter Syndrome, Sanfilippo Syndrome Type A and Pompe Disease at Upcoming 2026 WORLDSymposium™

Denali Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 4:30 PM EST - 6 months ago

Denali Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Denali Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 4:30 PM EST - 6 months ago

Denali Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Dec 30, 2025, 8:00 AM EST - 6 months ago

The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics' Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Dec 10, 2025, 12:14 AM EST - 7 months ago

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Dec 9, 2025, 4:01 PM EST - 7 months ago

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants

Denali Therapeutics Transcript: Investor Day 2025

Dec 4, 2025, 8:30 AM EST - 7 months ago

Denali Therapeutics Transcript: Investor Day 2025

Denali Therapeutics Slides: FY 2025

Dec 4, 2025, 8:30 AM EST - 7 months ago

Denali Therapeutics Slides: FY 2025

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

Dec 4, 2025, 7:00 AM EST - 7 months ago

Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement

RPRX

Denali Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Nov 18, 2025, 7:30 AM EST - 8 months ago

Denali Therapeutics Transcript: Jefferies London Healthcare Conference 2025

Denali Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 12, 2025, 8:40 AM EST - 8 months ago

Denali Therapeutics Transcript: Stifel 2025 Healthcare Conference

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:01 PM EST - 8 months ago

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

Denali Therapeutics Earnings release: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Denali Therapeutics Earnings release: Q3 2025

Denali Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 7:00 AM EST - 8 months ago

Denali Therapeutics Quarterly report: Q3 2025

Denali Therapeutics Slides: Corporate Presentation

Nov 5, 2025, 6:00 PM EST - 8 months ago

Denali Therapeutics Slides: Corporate Presentation

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Oct 13, 2025, 4:01 PM EDT - 9 months ago

Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 11:25 AM EDT - 10 months ago

Denali Therapeutics Transcript: Baird Global Healthcare Conference 2025

Denali Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 1:05 PM EDT - 11 months ago

Denali Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Denali Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 2:45 PM EDT - 11 months ago

Denali Therapeutics Transcript: Cantor Global Healthcare Conference 2025

The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 11 months ago

The Best Small-Cap Stocks to Buy Now

KYMR WAY

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 11, 2025, 4:01 PM EDT - 1 year ago

Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

Denali Therapeutics Quarterly report: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Denali Therapeutics Quarterly report: Q2 2025

Denali Therapeutics Earnings release: Q2 2025

Aug 11, 2025, 4:00 PM EDT - 1 year ago

Denali Therapeutics Earnings release: Q2 2025

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

Jul 7, 2025, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

Denali Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Jun 10, 2025, 1:20 PM EDT - 1 year ago

Denali Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference

Denali Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 4, 2025, 9:55 AM EDT - 1 year ago

Denali Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Denali Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 13, 2025, 5:20 PM EDT - 1 year ago

Denali Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

Denali Therapeutics Slides: Corporate Presentation

May 13, 2025, 7:00 AM EDT - 1 year ago

Denali Therapeutics Slides: Corporate Presentation

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

May 6, 2025, 4:01 PM EDT - 1 year ago

Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome

Denali Therapeutics Quarterly report: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Denali Therapeutics Quarterly report: Q1 2025

Denali Therapeutics Earnings release: Q1 2025

May 6, 2025, 4:00 PM EDT - 1 year ago

Denali Therapeutics Earnings release: Q1 2025

Denali Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Denali Therapeutics Proxy statement: Proxy Filing

Denali Therapeutics Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Denali Therapeutics Proxy statement: Proxy Filing

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program

Biotech stocks have been hit hard. Why they're a great value now.

Mar 27, 2025, 7:40 AM EDT - 1 year ago

Biotech stocks have been hit hard. Why they're a great value now.

PFE BHVN GPCR INSM MRK SWTX

Denali Therapeutics Transcript: Stifel 2025 Virtual CNS Forum

Mar 18, 2025, 2:30 PM EDT - 1 year ago

Denali Therapeutics Transcript: Stifel 2025 Virtual CNS Forum

Denali Therapeutics Slides: FY 2025

Mar 18, 2025, 2:30 PM EDT - 1 year ago

Denali Therapeutics Slides: FY 2025

Denali Therapeutics Transcript: UBS Virtual CNS Day 2025

Mar 17, 2025, 12:00 PM EDT - 1 year ago

Denali Therapeutics Transcript: UBS Virtual CNS Day 2025

Denali Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Mar 10, 2025, 1:40 PM EDT - 1 year ago

Denali Therapeutics Transcript: Leerink Global Healthcare Conference 2025

Denali Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 4, 2025, 3:10 PM EST - 1 year ago

Denali Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Feb 27, 2025, 4:01 PM EST - 1 year ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

Denali Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

Denali Therapeutics Earnings release: Q4 2024

Denali Therapeutics Annual report: Q4 2024

Feb 27, 2025, 4:00 PM EST - 1 year ago

Denali Therapeutics Annual report: Q4 2024

Denali Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Feb 11, 2025, 12:00 PM EST - 1 year ago

Denali Therapeutics Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Feb 6, 2025, 11:42 AM EST - 1 year ago

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Denali Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 14, 2025, 2:15 PM EST - 1 year ago

Denali Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Denali Therapeutics Slides: FY 2025

Jan 14, 2025, 2:15 PM EST - 1 year ago

Denali Therapeutics Slides: FY 2025

Denali Therapeutics ALS drug fails in mid-stage trial

Jan 6, 2025, 4:43 PM EST - 1 year ago

Denali Therapeutics ALS drug fails in mid-stage trial

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Jan 6, 2025, 4:30 PM EST - 1 year ago

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Dec 3, 2024, 12:30 PM EST - 1 year ago

Denali Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Denali Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 19, 2024, 2:25 PM EST - 1 year ago

Denali Therapeutics Transcript: Stifel 2024 Healthcare Conference

Denali Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Nov 19, 2024, 10:30 AM EST - 1 year ago

Denali Therapeutics Transcript: Jefferies London Healthcare Conference 2024

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 6, 2024, 4:01 PM EST - 1 year ago

Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Quarterly report: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Denali Therapeutics Quarterly report: Q3 2024

Denali Therapeutics Earnings release: Q3 2024

Nov 5, 2024, 6:00 PM EST - 1 year ago

Denali Therapeutics Earnings release: Q3 2024

Denali Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 19, 2024, 9:10 AM EDT - 1 year ago

Denali Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Denali Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Sep 5, 2024, 3:20 PM EDT - 2 years ago

Denali Therapeutics Transcript: Morgan Stanley 22nd Annual Global Healthcare Conference

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Sep 3, 2024, 8:00 AM EDT - 2 years ago

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Aug 14, 2024, 2:00 PM EDT - 2 years ago

Denali Therapeutics Announces Publication in Science Translational Medicine Demonstrating the Potential of the Oligonucleotide Transport Vehicle Platform to Achieve Broad Biodistribution of Antisense Oligonucleotides in the CNS and Muscle Following Intravenous Administration

Denali Therapeutics Quarterly report: Q2 2024

Aug 1, 2024, 7:00 AM EDT - 2 years ago

Denali Therapeutics Quarterly report: Q2 2024

Denali Therapeutics Earnings release: Q2 2024

Aug 1, 2024, 7:00 AM EDT - 2 years ago

Denali Therapeutics Earnings release: Q2 2024

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 1, 2024, 6:45 AM EDT - 2 years ago

Denali Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Denali Therapeutics Announces FDA Has Selected DNL126 (ETV:SGSH) for MPS IIIA (Sanfilippo Syndrome Type A) for START Pilot Program Intended to Accelerate Development of Rare Disease Therapies

Denali Therapeutics Slides: Corporate Presentation

May 14, 2024, 7:00 AM EDT - 2 years ago

Denali Therapeutics Slides: Corporate Presentation

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

May 7, 2024, 4:01 PM EDT - 2 years ago

Denali Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights

Denali Therapeutics Quarterly report: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Denali Therapeutics Quarterly report: Q1 2024

Denali Therapeutics Earnings release: Q1 2024

May 7, 2024, 4:00 PM EDT - 2 years ago

Denali Therapeutics Earnings release: Q1 2024

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

May 1, 2024, 8:00 AM EDT - 2 years ago

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Denali Therapeutics Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Denali Therapeutics Proxy statement: Proxy Filing

Denali Therapeutics Proxy statement: Proxy Filing

Apr 18, 2024, 8:00 AM EDT - 2 years ago

Denali Therapeutics Proxy statement: Proxy Filing

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Feb 27, 2024, 8:05 AM EST - 2 years ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Feb 27, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces $500 million Private Placement Equity Financing

Denali Therapeutics Annual report: Q4 2023

Feb 27, 2024, 7:00 AM EST - 2 years ago

Denali Therapeutics Annual report: Q4 2023

Denali Therapeutics Earnings release: Q4 2023

Feb 27, 2024, 7:00 AM EST - 2 years ago

Denali Therapeutics Earnings release: Q4 2023

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Feb 7, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapy Programs at WORLDSymposium™

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

Feb 1, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Presentations on Its Investigational Blood-Brain Barrier (BBB)-Crossing Enzyme Replacement Therapies at the Upcoming 2024 WORLDSymposium™

Denali Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 9, 2024, 1:30 PM EST - 2 years ago

Denali Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Jan 8, 2024, 8:00 AM EST - 2 years ago

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 7, 2023, 4:01 PM EST - 2 years ago

Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

Denali Therapeutics Quarterly report: Q3 2023

Nov 7, 2023, 4:00 PM EST - 2 years ago

Denali Therapeutics Quarterly report: Q3 2023

Denali Therapeutics Earnings release: Q3 2023

Nov 7, 2023, 4:00 PM EST - 2 years ago

Denali Therapeutics Earnings release: Q3 2023

Denali Therapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Sep 12, 2023, 11:30 AM EDT - 3 years ago

Denali Therapeutics Transcript: Morgan Stanley 21st Annual Global Healthcare Conference 2023

Denali Therapeutics Slides: FY 2023

Sep 12, 2023, 11:30 AM EDT - 3 years ago

Denali Therapeutics Slides: FY 2023

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

Sep 11, 2023, 6:30 AM EDT - 3 years ago

Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer

FHTX MCRB MRNA SANA

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Aug 30, 2023, 8:30 AM EDT - 3 years ago

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 8, 2023, 4:01 PM EDT - 3 years ago

Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Denali Therapeutics Quarterly report: Q2 2023

Aug 8, 2023, 4:00 PM EDT - 3 years ago

Denali Therapeutics Quarterly report: Q2 2023

Denali Therapeutics Earnings release: Q2 2023

Aug 8, 2023, 4:00 PM EDT - 3 years ago

Denali Therapeutics Earnings release: Q2 2023

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

Jun 21, 2023, 6:00 AM EDT - 3 years ago

Flagship Pioneering Unveils Empress Therapeutics to Revolutionize Drug Discovery by Applying the Power of Genetics to Identify Small Molecule Drugs

FHTX MCRB MRNA SANA

Denali Therapeutics Transcript: Study Result

Jun 20, 2023, 8:30 AM EDT - 3 years ago

Denali Therapeutics Transcript: Study Result

Denali Therapeutics Press release: Study Result

Jun 20, 2023, 8:30 AM EDT - 3 years ago

Denali Therapeutics Press release: Study Result

Denali Therapeutics Slides: Study Result

Jun 20, 2023, 8:30 AM EDT - 3 years ago

Denali Therapeutics Slides: Study Result

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

Jun 20, 2023, 7:00 AM EDT - 3 years ago

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)

Denali Therapeutics Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

Jun 13, 2023, 6:20 PM EDT - 3 years ago

Denali Therapeutics Transcript: Goldman Sachs 44th Annual Global Healthcare Conference

Denali Therapeutics Transcript: Bank of America Securities 2023 Healthcare Conference

May 10, 2023, 11:40 AM EDT - 3 years ago

Denali Therapeutics Transcript: Bank of America Securities 2023 Healthcare Conference

Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

May 8, 2023, 4:01 PM EDT - 3 years ago

Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights

Denali Therapeutics Quarterly report: Q1 2023

May 8, 2023, 4:00 PM EDT - 3 years ago

Denali Therapeutics Quarterly report: Q1 2023

Denali Therapeutics Earnings release: Q1 2023

May 8, 2023, 4:00 PM EDT - 3 years ago

Denali Therapeutics Earnings release: Q1 2023

Denali Therapeutics Proxy statement: Proxy Filing

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Denali Therapeutics Proxy statement: Proxy Filing

Denali Therapeutics Proxy statement: Proxy Filing

Apr 18, 2023, 8:00 AM EDT - 3 years ago

Denali Therapeutics Proxy statement: Proxy Filing

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

Apr 12, 2023, 8:00 AM EDT - 3 years ago

Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

Apr 10, 2023, 8:00 AM EDT - 3 years ago

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Feb 27, 2023, 4:01 PM EST - 3 years ago

Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Denali Therapeutics Annual report: Q4 2022

Feb 27, 2023, 4:00 PM EST - 3 years ago

Denali Therapeutics Annual report: Q4 2022

Denali Therapeutics Earnings release: Q4 2022

Feb 27, 2023, 4:00 PM EST - 3 years ago

Denali Therapeutics Earnings release: Q4 2022

Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™

Feb 22, 2023, 4:33 PM EST - 3 years ago

Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

Feb 15, 2023, 4:01 PM EST - 3 years ago

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™